Results 241 to 250 of about 7,031,181 (311)

Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance. [PDF]

Cells
Ivanenko K, Shaymardanov R, Prassolov V, Lebedev T.   +3 more
europepmc   +1 more source

Exon 7 splicing of ERα predicts poor prognosis and increases phenotypic heterogeneity in luminal a subtype breast cancer

FEBS Open Bio, EarlyView.
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui, Taobo Hu, Thomson Christian Husein, Wai Hei Shek, Bingrong Chen, Depeng Wang, Shu Wang, Weichuan Yu, Xiaodan Fan, Mengping Long, Toyotaka Ishibashi   +10 more
wiley   +1 more source

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease. [PDF]

Front Nutr
Tanaka T, Suda G, Ohara M, Maehara O, Yoda T, Fu Q, Yang Z, Yasuura N, Meno A, Sasaki T, Kohya R, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ohnishi S, Sakamoto N.   +16 more
europepmc   +1 more source

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source

Evaluation of the vascular remodeling markers elastin, vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor receptor 2 (VEGFR2), and nitric oxide in patients with varicose veins. [PDF]

Kardiochir Torakochirurgia Pol
Shaalan SH, Auda FM.
europepmc   +1 more source

Real-World Study Assessing Characteristics and Treatment Patterns of Patients With Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2-Low Stage IV Breast Cancer: A Multicenter Retrospective Study. [PDF]

JCO Precis Oncol
Tan CJ, Willis C, Au T, Schabath MB, Li C, Kelley K, Xu X, Park L, Lam C, Mehta S, Kwong J, Brixner D, Stenehjem D.   +12 more
europepmc   +1 more source

Scaffolds with spatiotemporally controlled growth factor delivery and cyclodextrin-enabled antagonism of growth factor receptor sequestration promote cutaneous wound healing. [PDF]

NPJ Regen Med
Marjanovic J, Jurczuk V, Tose LV, Cintron Diaz Y, Fernandez Lima F, Abdo Abujamra B, Danker S, Jabori S, Singh D, Burgess JL, Tam J, Samandari M, Stone RC, Davis SC, Kirsner RS, Tomic-Canic M, Andreopoulos FM, Jozic I.   +17 more
europepmc   +1 more source